As
AstraZeneca
Regulatory Status Disclosed
Overview
AstraZeneca utilizes various AI tools and strategies across its research and development pipeline, primarily focusing on drug discovery, clinical trial optimization, and disease understanding. These tools are designed for researchers, clinical trial specialists, and potentially clinicians in various care settings involved in pharmaceutical development and patient management.
- MILTON (MachIne Learning with phenoType associatiONs): This AI research tool predicts over 1,000 diseases before diagnosis by analyzing comprehensive data from biobanks. It aims to accelerate the discovery of new drug targets and biomarkers, potentially aiding in earlier disease detection and preventative medicine.
- Drug Discovery and Design: AstraZeneca integrates AI to identify promising drug targets, design novel molecules, antibodies, and proteins, and optimize drug candidates. This involves analyzing vast chemical and biological databases to predict drug-target interactions and molecular stability.
- Clinical Trial Optimization: AI is used to streamline clinical trial design, accelerate patient recruitment, and create virtual control groups. It analyzes real-world evidence and health record data to optimize trial protocols and predict patient responses to treatment.
- Disease Understanding and Early Detection: AI helps analyze large datasets, including molecular imaging, to understand disease mechanisms and identify patterns that can lead to earlier intervention.
These AI applications fit into the workflow by augmenting traditional research methods, providing speed, scale, and insights that were previously unattainable. The goal is to accelerate the development and delivery of medicines by enhancing efficiency and precision at various stages, from target identification to patient selection for trials.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered drug discovery
- Target identification
- Molecule design and optimization
- Clinical trial optimization
- Data integration and analysis
- Predictive analytics
Use Cases
- Accelerating pharmaceutical R&D
- Identifying novel drug targets
- Optimizing drug molecule properties
- Improving clinical trial efficiency
What Physicians Need to Know
Molecule Screening Capability
AstraZeneca utilizes AI to accelerate drug discovery from years to weeks, generating novel therapeutic molecules and optimizing existing compound libraries. Their AI systems analyze biological relationships, predict molecular behavior, and design therapeutic compounds with precision. They have developed an AI framework, MapDiff, for inverse protein folding, which significantly improves accuracy in designing novel therapeutic proteins. Additionally, AI models help prioritize molecules for further development, optimizing them for desirable therapeutic properties. Their Discovery Centre (DISC) can screen 1 million compounds daily.
Clinical Trial Matching
AI algorithms are used to recruit suitable patients for clinical trials by analyzing patient profiles and medical records. This includes combining biomarkers, imaging, and real-world data to match the right therapy to the right person, increasing the likelihood of benefit. AstraZeneca also uses AI to refine patient selection by simulating the impact of inclusion and exclusion criteria, identifying potential recruitment challenges. They have partnered with Oncoshot to leverage AI-enabled patient-to-trial matching technology to streamline recruitment for cancer clinical trials.
Real-World Evidence Analysis
AstraZeneca's AI analyzes real-world evidence, including patient data, treatment outcomes, and healthcare patterns, to inform drug development decisions and optimize therapeutic strategies. This system processes healthcare records and treatment patterns to identify therapeutic opportunities and validates AI predictions through actual clinical experience. Real-time data analysis ensures efficient trial monitoring and faster decision-making. Real-world clinical data feedback closes development loops, validating AI predictions and improving therapeutic success rates.
Genomic Data Integration
AI integrates layers of biology, including genes, proteins, and cell signals, to pinpoint and validate high-confidence targets, revealing key disease mechanisms. Their Centre for Genomics Research fuels R&D with over 1.7 million human genomes and matched clinical insights. AstraZeneca's MILTON, a machine learning research tool, predicts over 1,000 diseases, sometimes 10-15 years before clinical diagnosis, by drawing on comprehensive data from nearly 500,000 participants in UK Biobank, including 67 routine clinical biomarkers and 3,000 plasma protein measurements.
Literature Mining
AstraZeneca leverages Natural Language Processing (NLP) to process and analyze a vast library of scientific literature and data sources, facilitating the integration of disjointed data. They have collaborated with IQVIA, using their AI-Assisted Literature Review Solution, to reduce the number of documents for manual screening in systematic literature reviews by seven-fold, saving significant time and resources. This solution uses a text-mining algorithm to rapidly identify relevant papers from millions of MEDLINE abstracts. They also have a collaborative project with the National Centre for Text Mining (NaCTeM) to enhance abilities to extract information from literature for drug discovery.
Target Identification
AI algorithms identify potential drug targets by analyzing vast datasets and predicting disease mechanisms. AstraZeneca's AI target identification demonstrates advanced disease understanding, identifying therapeutic opportunities for conditions that traditional research approaches struggle to address effectively. This involves analyzing complex disease mechanisms, genetic factors, and biological pathways to identify intervention points. AI integrates layers of biology to pinpoint and validate high-confidence targets.
Safety Signal Detection
AI continuously monitors incoming safety data in clinical trials and alerts scientists to safety signals that need attention. AstraZeneca has implemented 'Watcher,' a novel AI-based decision support system for continuous monitoring of safety data in early phase clinical trials. They have also partnered with ArisGlobal for LifeSphere Signal and Risk Management, a solution with smarter signal detection algorithms to reduce noise-to-signal ratio and streamline signal detection and risk management. AstraZeneca is collaborating with the FDA to modernize clinical trial monitoring using AI, aiming to reduce the time lag for safety signal detection from years to real-time.
Collaboration Features
AstraZeneca complements its in-house AI capabilities through an ecosystem of partnerships with academia, specialized AI companies, regulators, and patients. They have strategic alliances with institutions like Stanford Medicine, focusing on novel AI-driven approaches for various disease areas and improving clinical trial design. Collaborations include partnerships with BenevolentAI, Turbine, and Immunai to enhance AI capabilities and access specialized expertise. They have expanded their AI oncology collaboration with Immunai, leveraging Immunai's AMICA-OS AI operating system for insights across oncology drug development. AstraZeneca also collaborates with Tempus and Pathos AI to develop a large oncology foundation model for applications like clinical trial matching and study design.
Publication Support
While not explicitly detailed as 'publication support' in the provided text, AstraZeneca's use of AI in literature mining, particularly with IQVIA's AI-Assisted Literature Review Solution, significantly reduces the human effort and time required for systematic literature reviews. This efficiency in identifying and screening relevant scientific papers would indirectly support the preparation of evidence-based publications by streamlining the literature review process.
Physician Tip
Physicians should be aware that AstraZeneca is heavily integrating AI across drug discovery and clinical development. This means potential for faster access to novel therapies, more precisely targeted treatments based on genomic and real-world data, and more efficient clinical trials. AI-powered tools like MILTON may enable earlier disease detection, potentially impacting screening and preventative strategies. The use of AI in clinical trial matching could lead to more tailored trial opportunities for patients. Additionally, AI-driven safety signal detection aims to enhance patient safety monitoring in real-time. Physicians should stay informed about specific AI applications relevant to their specialties as these technologies evolve and translate into clinical practice.
AstraZeneca's AI strategy involves deep integration across its R&D value chain, from target identification to clinical trial optimization and regulatory strategy. They utilize a unified linked data foundation that integrates multimodal claims and EMR data, market research, domain intelligence, medical research (including clinical trial reports and publications), conference proceedings, NCCN guidelines, and internal CRM data. Key integrations include partnerships with AI companies like BenevolentAI, Turbine, Immunai, Qure.ai, Perceptra, and academic institutions such as the University of Sheffield, University of Cambridge, and Stanford Medicine. They also leverage platforms like IQVIA's AI-Assisted Literature Review Solution for literature mining and ArisGlobal's LifeSphere Signal and Risk Management for safety signal detection. AstraZeneca also uses Databricks for scalable data pipelines and AWS Sagemaker for streamlining machine learning model deployment.
Details
| Category | Drug Discovery & Research, General Productivity (AI Assistants) |
| Pricing |
Unknown
|
| Mobile App | 1 |
| Languages | AstraZeneca offers an online learning platform with content and programs available in over 10 languages, and a foreign language skills program offering over 70 different languages for employees. Their Health Gate mobile app is available in Arabic and English. |
| Training | Unknown |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Not applicable AI-estimated AstraZeneca has received FDA approval for several drugs. In September 2026, its breast cancer pill, camizestrant (brand name Etcamah), received accelerated approval for use in combination with other cancer medicines for patients with a genetically driven form of metastatic breast cancer. This marks the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA (ctDNA) before imaging tests show disease progression. In May 2026, the FDA also approved Fasenra (benralizumab) for the treatment of hypereosinophilic syndrome in patients 12 years and older. |
| Integrations | |
| EHR | Not specified |
| Specialties | Hematology, Oncology, Pathology |
Social Proof
| Customers | unknown |
| Notable | unknown |
Support & Reliability
| Training Provided | Unknown |
What the Web Says
AstraZeneca is heavily investing in AI and data science, integrating it across its operations from R&D to manufacturing and clinical trials. The company emphasizes a responsible and ethical approach to AI, with a focus on human oversight and data privacy. AstraZeneca's CEO highlights AI's role in accelerating drug development and improving decision-making.
Overall: PositiveStrengths
- Accelerates drug development and improves decision-making.
- Enhances understanding of diseases and identification of drug targets.
- Reduces time for patient recruitment in clinical trials.
- Improves operational efficiency and productivity within data science and research teams.
- Focus on ethical and responsible AI use with human oversight.
- Pioneering AI clinical trials at a national healthcare system scale.
Limitations
- Challenges in seamless integration of diverse data sources.
- Managing complex AI infrastructure requiring constant upkeep.
- Creating a cohesive environment for various machine learning tools.
- Ethical considerations related to data privacy and accuracy of AI-generated outputs.
- Potential for AI in drug discovery to be overhyped, with human intuition still playing a significant role.
- Learning curve for advanced AI dashboards and potential for slow data processing with some tools.
Based on reviews from: CTO Magazine, Reddit, AstraZeneca (Official Website), LockedIn AI, Indeed.com, G2, Capterra, YouTube
Last updated: 2026-10-12
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate AstraZeneca
Press & Coverage
MobiHealthNews
Exclusive: Pangaea Data, AstraZeneca leverage AI to detect rare and hard-to-diagnose diseases
Pangaea Data and AstraZeneca are collaborating to use AI to identify undiagnosed and undertreated patients, support clinical trials, and advance precision therapies, utilizing Microsoft's Azure AI infrastructure. This multi-year agreement builds on a previous collaboration with Alexion, AstraZeneca's rare-disease unit.
2025-12
AstraZeneca
AI Drug Discovery: MapDiff & Edge Set Attention Breakthroughs - AstraZeneca
AstraZeneca highlights its commitment to AI in drug discovery, showcasing collaborations with the University of Sheffield and Cambridge that led to breakthroughs like MapDiff, an AI framework for inverse protein folding. These innovations aim to accelerate drug discovery and design.
2025-10
The Chemical Engineer
AstraZeneca strikes US$555m deal to commercialise AI-discovered immunology drugs
AstraZeneca has finalized a deal worth up to US$555 million to commercialize immunology therapies developed by Algen Biotechnologies using AI to analyze RNA changes and identify therapeutic targets. AstraZeneca's chief data scientist, Jim Weatherall, cautioned against AI hype, emphasizing its role as a tool.
2025-10
PR Newswire
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
SOPHiA GENETICS and AstraZeneca are expanding their partnership to leverage SOPHiA GENETICS's multimodal AI Factories for analyzing healthcare data and generating insights to optimize breast cancer outcomes. This collaboration aims to understand disease biology and biomarkers for tailored treatments.
2025-08
AI News
AstraZeneca bets on in-house AI to speed up oncology research - AI News
AstraZeneca is acquiring Modella AI to integrate data, models, and AI talent directly into its oncology research teams, aiming to shorten the time from research data to decisions affecting trial design and patient selection. This acquisition reflects a long-term strategy of building internal AI capabilities.
2026-01
CTO Magazine
AI for Smarter Solutions: Inside AstraZeneca's AI Strategy - CTO Magazine
AstraZeneca's AI strategy focuses on integrating AI as core infrastructure across R&D, manufacturing, and operations to meet its 'Ambition 2030' goals. The company has invested in AI infrastructure, proprietary data assets, and partnerships, alongside an enterprise-wide AI upskilling program for employees.
2026-02
Quartz
FDA launches real-time clinical trial monitoring with AI - Quartz
The FDA has initiated real-time clinical trial monitoring using AI, with AstraZeneca participating in an early phase 2 trial for mantle cell lymphoma. This allows the agency to view safety signals and trial endpoints as they occur, aiming to reduce the time from study initiation to approval.
2026-04
Business Chief
AstraZeneca CEO: AI will Change the Pharmaceutical Industry | Business Chief
AstraZeneca CEO Pascal Soriot states that AI is already embedded across the company, from discovery to commercial operations, and is delivering measurable impact. He highlights AI's role in enhancing drug discovery, optimizing molecules, and improving the probability of success in late-stage trials.
2026-06
Videos
Product demos, reviews, and walkthroughs for AstraZeneca.
Loading videos...
Frequently Asked Questions
AstraZeneca's main therapeutic areas for drug discovery and development include Oncology, Cardiovascular, Renal and Metabolism (CVRM), Respiratory & Immunology, and Rare Diseases. They also have a focus on Infectious Disease.
AstraZeneca is committed to high standards of conduct, adhering to global regulations and ethical guidelines. They have a comprehensive US Compliance Program to prevent unlawful conduct and promote ethical behavior, which includes policies on anti-bribery, responsible sales and marketing, and patient safety. The company also ensures transparency in clinical trials by registering studies globally and publishing results, whether favorable or unfavorable.
AstraZeneca evaluates requests for early or post-trial access to investigational medicines for patients with serious or life-threatening conditions who lack other treatment options. Access is considered if it won't compromise clinical development, the patient can't participate in a trial, and the benefit outweighs the risk. All requests must come from the patient's treating physician.
AstraZeneca operates in a highly competitive pharmaceutical market. Some of its top competitors across various therapeutic areas include Pfizer, Novartis, GSK, Amgen, Merck, Johnson & Johnson, Regeneron, Bristol Myers Squibb, and Eli Lilly. For example, Regeneron's Dupixent competes with AstraZeneca/Amgen's TEZSPIRE and AstraZeneca's FASENRA in asthma and nasal polyps.
AstraZeneca has been adjusting its pricing strategy for new drug launches in response to policies like the U.S. 'most-favoured-nation' policy, which aims to tie U.S. medicine prices to those in other wealthy countries. This has led to agreements to offer discounted prices for certain medications to Medicaid and directly to American patients.
Drug discovery is a long and complex process, often taking over 10 years and requiring significant resources. Early research involves screening thousands of compounds, with many being terminated due to insufficient efficacy or unacceptable side effects. AstraZeneca addresses these challenges through a staged approach of deepening disease understanding, rigorously testing drug candidates, and running clinical trials.
AstraZeneca aims to reach $80 billion in annual revenue by 2030, driven by its growing oncology business and investments in newer technologies like obesity treatments and cell therapies. The company is expanding its research and manufacturing operations globally and has a robust pipeline of investigational therapies across its key therapeutic areas.
Suggest an Edit →
| Last Verified: 2026-10-12 | First Added: 2026-10-11